Estudo randomizado: Em pacientes internados com Covid-19 e D-dímero elevado, a estratégia de anticoagulação em dose plena baseada em rivaroxabam (dose plena de heparinas em pacientes instáveis) + rivaroxabam até o dia 30 não foi melhor do que a anticoagulação profilática e aumentou o risco de sangramento.

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet

Relacionado: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.

Comentário no Twitter

Thanks @CMichaelGibson. Another important contribution from the Brazilian Coalition team and investigators in Brazil. Our 6th trial completed in 12 months. Go coalition!!!! https://t.co/TDUr1RukuW

— Renato D Lopes (@RenatoDLopes1) June 4, 2021